Abstract 117P
Background
Hepatoid adenocarcinoma of stomach (HAS) is a rare subtype of gastric cancer (GC) with hepatocyte-like differentiation and a dismal prognosis. Although HAS has different histological and molecular properties and more aggressive biological behavior, most patients with HAS still receive the same regimen as usual GC. A comprehensive understanding of the molecular properties of HAS may provide insights into personalized diagnosis and treatment, however, this area is under-studied.
Methods
We aimed to explore methylome and transcriptome profiling of HAS in a relatively precise scenario. The laser capture microdissection (LCM) was used to isolate thirty-two formalin fixed paraffin-embedded (FFPE) tissue into gastric adenocarcinoma section (GAC) and hepatocellular-like section (HAS). According to the manufacturer's protocol, DNA-associated methylation sequencing and RNA-associated transcriptome sequencing were performed.
Results
With Laser-Capture Microdissection (LCM) technique, we separate HAS FFPE sample into gastric adenocarcinoma component (GAC) and HAS component. The whole genome RNAseq and methylation sequencing (GMseq) were used to explore HAS expression patterns and methylation modification profile. We found that differentially methylated cytosine was effective in distinguishing GAC from HAS, and stem cell-related gene expression and pathway enrichment were higher in GAC than in HAS. Correspondingly, HAS showed TNFSF15 gene significantly hypermethylation and lower expression features. In addition, in vivo xenograft models derived from TNFSF15 knockout cells showed higher aggressiveness and hepatocyte-like gene expression. Our study sheds light on the critical role of TNFSF15 in HAS transdifferentiation, and intervening methylation of TNFSF15 may be a clinical option to improve prognosis and reduce metastasis.
Conclusions
In summary, we found that the GAC component has the expression features of pluripotent stem cells and mesothelial cells, and the HAS component has the features of hepatoblast and mature hepatocytes. We propose that GAC mesoderm and endoderm dedifferentiation bias TME as the key role to HAS transdifferentiation and TNFSF15 may be a key regulatory factor in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Development of a cadherin-17 (CDH17) immunohistochemistry assay for use as a companion diagnostic for cabotamig in gastrointestinal cancers
Presenter: Dennis Wong
Session: Poster session 08
184P - From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis
Presenter: Kristian Egebjerg
Session: Poster session 08
185P - Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP)
Presenter: Maria Pouyiourou
Session: Poster session 08
186P - Differences in antigen and immune marker expression in lymphoepithelioma-like carcinoma (LELC) and nasopharyngeal carcinoma (NPC): A multiplex immunohistochemistry (mIHC), spatial transcriptomic and multiplex immunofluorescence (mIF)-based analysis
Presenter: Daniel Peh
Session: Poster session 08
187P - Organoid growth-based oncological sensitivity test (OncoSensi) for predicting radiation therapy outcomes in pharyngeal and esophageal cancer
Presenter: Dong Woo Lee
Session: Poster session 08
188P - Integration of immunohistochemistry and transcriptomics reveals new insights into the immune landscape of soft-tissue sarcomas
Presenter: Giulia Petroni
Session: Poster session 08
189P - An image-based deep learning prediction model for characterization of the drug tolerant persister cell state
Presenter: Lauren Cech
Session: Poster session 08
190P - A large scale proteogenomics atlas for precision oncology research
Presenter: Timothy Anthony Yap
Session: Poster session 08
191P - Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors
Presenter: Francesco Facchinetti
Session: Poster session 08
192P - Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers
Presenter: Daniel Palmer
Session: Poster session 08